Plain-English translation of NCT07553754 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying tiny particles called exosomes that circulate in your blood. These exosomes carry genetic material from your cancer that might show whether your prostate cancer has spread to your bones. The goal is to develop a simple blood test that could replace more expensive and radiation-exposing imaging scans for some patients.
Current blood tests and imaging methods don't reliably catch bone metastasis early enough, and the best imaging scan available (PSMA PET) is expensive, not widely available, and uses radiation. This study aims to create a blood-based test that can safely rule out bone metastasis in low-risk patients, reducing unnecessary scans and costs.
You likely qualify if…
You likely don't qualify if…
You will provide a single 10-milliliter blood sample (about 2 teaspoons), collected before any treatment or biopsy. You will also undergo a PSMA PET imaging scan to determine your bone metastasis status. The study enrolls 1,000 patients across multiple medical centers and uses different groups of patients to discover, develop, and validate the blood test over time. Your participation is observational—researchers are analyzing your blood and imaging results to build and test the new biomarker.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jianhua Jiao, MD.
Xijing Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.